Standard BioTools Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Standard BioTools Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-13.4×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 55% of Healthcare companies in United States.
Cash Locked Ratio
$33For every $100 of sales, $33 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $30 tied up three years earlier.
More money tied up than 71% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 13%
Sales fell 13% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-13% / +45%In 3 years sales changed by -13% while total assets changed by +45%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-13.5×Operating cash was negative last year, while some debt falls due within a year.
Higher than 51% of Healthcare companies in United States.
Cash Cushion Ratio
+63%Cash, after subtracting all debt, equals 63% of its market value (net cash).
Higher than 81% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Standard BioTools Inc. made a loss over the last year. Standard BioTools Inc. owes $0.14 for every $1 it owns. Standard BioTools Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossStandard BioTools Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.46The share price is 0.46 times Standard BioTools Inc.'s book value per share, lower than 92% of Healthcare companies in United States.
Market cap
$250 MThe total market value of all of Standard BioTools Inc.'s shares at today's price (share price × number of shares), smaller than 55% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$540 MWhat Standard BioTools Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.38Net worth divided by the number of shares. The share price of $0.64 is 0.5 times this, which is the P/B above.
Return on equity (ROE)
-11.2%Standard BioTools Inc. lost 11.2% of its shareholders' money over the last year, higher than 70% of Healthcare companies in United States.
Owes vs Owns
0.14×Standard BioTools Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Dividend yield
NoneStandard BioTools Inc. does not currently pay a dividend.
Revenue growth
-6%Revenue fell 6% in the year to Dec 2025, and shrank 4% a year on average over 3 years.
Profit growth
LossStandard BioTools Inc. made a loss in each of the last two years.
Profit margin
-87.8%Standard BioTools Inc. lost $88 for every $100 of revenue.
Interest cover
Not coveredStandard BioTools Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashStandard BioTools Inc. held $157 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Standard BioTools Inc.: $250 M ÷ $540 M (30 Jun 2026) = 0.5.
What is Standard BioTools Inc.'s return on equity?
Standard BioTools Inc. lost 11.2% of its shareholders' money over the last year, higher than 70% of Healthcare companies in United States.
How much does Standard BioTools Inc. owe compared with what it owns?
Standard BioTools Inc. owes $0.14 for every $1 it owns (low), lower than 81% of Healthcare companies in United States.
Does Standard BioTools Inc. pay a dividend?
No. Standard BioTools Inc. does not currently pay a dividend.
Is Standard BioTools Inc.'s revenue growing?
Revenue fell 6% in the year to Dec 2025, and shrank 4% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.